OTCMKTS:NMUS Nemus Bioscience (NMUS) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free NMUS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.65▼$17.7552-Week Range N/AVolume1.00 million shsAverage Volume377,395 shsMarket Capitalization$87.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nemus Bioscience alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Nemus Bioscience Stock (OTCMKTS:NMUS)Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. NMUS Stock News HeadlinesApril 23, 2024 | americanbankingnews.comNemus Bioscience (OTCMKTS:NMUS) Stock Price Crosses Below 50-Day Moving Average of $10.66April 19, 2024 | finance.yahoo.comYield10 Bioscience, Inc. (YTEN)April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 16, 2024 | morningstar.comAssembly Biosciences Inc ASMBSeptember 5, 2023 | money.usnews.comSagimet Biosciences Inc - Ordinary Shares - Class AApril 27, 2023 | finance.yahoo.comSatellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible DebenturesApril 6, 2023 | finanznachrichten.deCrown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting BiobankFebruary 24, 2023 | finance.yahoo.comPsycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSDApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.January 27, 2023 | finance.yahoo.comSN BioScience and Boryung Announce the Licensing Agreement on Generic Version of AbraxaneJanuary 27, 2023 | yahoo.comCrown Bioscience to Acquire Indivumed’s Service Business and Supporting BiobankJanuary 27, 2023 | finance.yahoo.comRenaissance BioScience Corp. and Timeless Capital Corp. Enter into Letter of IntentOctober 26, 2022 | finance.yahoo.comBioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital HealthSeptember 23, 2022 | finance.yahoo.comNeurocrine Biosciences, Inc. (NBIX)See More Headlines Receive NMUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryCannabis Current SymbolOTCMKTS:NMUS CUSIPN/A CIKN/A Webwww.nemusbioscience.com Phone949-396-0330FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-924.42% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / BookN/AMiscellaneous Outstanding Shares133,908,000Free FloatN/AMarket Cap$87.04 million OptionableNot Optionable Beta-0.04 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Brian S. Murphy (Age 61)CEO, Chief Medical Officer & Director Dr. Avtar S. Dhillon (Age 57)Exec. Chairman Mr. Douglas A. Cesario (Age 44)Chief Financial Officer Ms. Wendy CunningVP of Bus. OperationsKey CompetitorsAtara BiotherapeuticsNASDAQ:ATRASELLAS Life Sciences GroupNASDAQ:SLSAbeona TherapeuticsNASDAQ:ABEOReviva PharmaceuticalsNASDAQ:RVPHIMACNASDAQ:IMACView All Competitors NMUS Stock Analysis - Frequently Asked Questions How were Nemus Bioscience's earnings last quarter? Nemus Bioscience Inc (OTCMKTS:NMUS) announced its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter. What other stocks do shareholders of Nemus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF), KushCo (KSHB), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Unrivaled Brands (TRTC), BOTS (MCIG) and Cronos Group (CRON). How do I buy shares of Nemus Bioscience? Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NMUS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nemus Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
